Advanced PDX Tumor Biology Platforms for Drug Advancement
Presented by Amy Wesa, Director IO R&D at Champions Oncology
- Harnessing large collections of PDX models for more resolute efficacy predictions and the discovery of new therapeutic targets, resistance mechanisms, and biomarker signatures of response.
- How robust systems of myeloid engraftment, including hematopoietic stem cells for immune-oncology modeling and AML engraftment for high throughput multi patient in vivo screens, have now provided expanded PDX screening with a wider scope of therapeutic agents.
- The advancement of coupled-PDX trials, where clinical trials are combined with companion PDX studies to help guide follow-on trial design.